心脏移植后免疫抑制手段中的一种潜在药物：贝拉西普。
A potential drug in the armamentarium of post-cardiac transplantation immunosuppression: belatacept.
作者信息
Sharma Dhruva, Sharma Neha
机构信息
Department of Cardiothoracic & Vascular Surgery, SMS Medical College & Attached Group of Hospitals, Jaipur, India.
Department of Pharmacology, SMS Medical College, Jaipur, India.
出版信息
Indian J Thorac Cardiovasc Surg. 2020 Nov;36(6):625-628. doi: 10.1007/s12055-020-00991-4. Epub 2020 Jul 10.
Undeterred by all the advancement in the field of cardiac transplantation, heart transplant rejection remained its mammoth quandary. Management of heart transplant recipients has drastically improved with current regimens of immunosuppressive drugs. The adverse effects of calcineurin inhibitors are lacking with the use of belatacept, which is a costimulation inhibitor that interferes with the interaction between CD28 on T cells and the B7 ligands on antigen-presenting cells. It was originally approved for use in renal transplant recipients but it has shown promising results in heart transplant recipients.
尽管心脏移植领域取得了诸多进展，但心脏移植排斥反应仍然是一个巨大的难题。目前的免疫抑制药物方案已使心脏移植受者的管理有了显著改善。使用贝拉西普（一种共刺激抑制剂，可干扰T细胞上的CD28与抗原呈递细胞上的B7配体之间的相互作用）时，钙调神经磷酸酶抑制剂的不良反应并不存在。它最初被批准用于肾移植受者，但在心脏移植受者中也显示出了令人鼓舞的结果。
Zotero 插件